[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ohio State University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":620},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,126,0,25,[9,45,69,81,111,133,160,183,215,235,262,289,317,342,366,387,413,432,454,478,503,530,555,579,601],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053297","phase-3-delaying-the-onset-of-nearsightedness-until-treatment-donut-clinical-trial-100053297",false,"NCT07567040","Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial","DONUT","Inclusion Criteria:\n\n* Refractive Error (cycloplegic autorefraction, spherical equivalent, at least one eye, inclusive) 6 years: -0.74 D to +0.75 D 7 and 8 years: -0.74 D to +0.50 D 9 and 10 years: -0.74 D to +0.25 D 11 years: -0.74 D to plano\n* Neither eye has -0.75 D or more myopia, spherical component\n* Anisometropia: Less than 1.50 D difference between OD and OS, cycloplegic autorefraction, spherical equivalent\n* Astigmatism: Less than 1.50 DC in both eyes by cycloplegic autorefraction\n* Successfully complete run-in period: take at least 90% of unit dose artificial tears for 2 to 4 weeks (# of unit-dose vials used divided by # nights since baseline visit must equal 0.90 or greater)\n\nExclusion Criteria:\n\n* If Visit 2 (randomization visit) is not completed within 4 weeks of the baseline, eligibility visit.\n* Presence of strabismus (intermittent or constant) based on unilateral cover test at distance and near\n* Known allergy to atropine\n* Systemic issues that may affect accommodation or convergence (e.g., multiple sclerosis, myasthenia gravis, Graves ophthalmopathy, diabetes mellitus, Parkinson's disease, Down syndrome, etc.)\n* Ocular disease (e.g., congenital glaucoma, retinal disease, nystagmus, amblyopia, etc.)\n* Ocular surgery (e.g., cataracts, strabismus)\n* Any previous myopia prevention\u002Fcontrol therapy (e.g., atropine, soft contact lenses, orthokeratology, myopia control spectacles, etc.) for more than one month\n* Pregnancy by self-report",true,"ALL","6 Years","11 Years",{"count":22,"type":23},664,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","The aims of this clinical trial will test whether or not the onset of nearsightedness is delayed in a group of children randomized to nightly drops in 0.05% atropine in both eyes, in comparison to children who receiving nightly placebo drops in both eyes. The primary outcome is the two-year cumulative incidence of nearsightedness. The second aim of this project will determine whether atropine is associated with slower eye growth in children receiving nightly drops of atropine versus placebo.",[29],"Myopia",[31],"prevention","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2026-05-27",{"date":40,"type":23},"2028-05-15",{"name":42,"class":43},"Ohio State University","OTHER",14,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100054046","phase-2-lidocaine-patch-vs-intradermal-lidocaine-for-epidural-needle-insertion-pain-a-randomized-trial-100054046","NCT07700108","Lidocaine Patch vs Intradermal Lidocaine for Epidural Needle Insertion Pain: A Randomized Trial","Prospective, Single-Center, Randomized, Double-Blind, Clinical Trial for the Evaluation of Pain Associated With the Epidural Tuohy Needle Insertion With Prior Administration of 4% Lidocaine Patch or Intradermal Lidocaine Injection in Parturient Women Requesting Epidural for Analgesia Management","Inclusion Criteria:\n\n* o Age ³ 18 years old\n\n  * Parturient women requesting neuraxial anesthesia\u002Fanalgesia (epidural or CSE) for vaginal or Cesarean Delivery\n  * Ability to consent in English\n\nExclusion Criteria:\n\n* o Less than 30 minutes of lidocaine patch placement prior to epidural placement\n\n  * Administration of opioids in the 4 hours before study enrollment\n  * IV magnesium sulfate within the last 24 hours\n  * Diabetes mellitus (Type I and II)\n  * Neurocardiogenic signs or symptoms (e.g., dizziness, lightheadedness, bradycardia, and syncope) during IV cannulation\n  * Cervical dilation \\>6 cm (if in labor).\n  * Spinal anesthesia\n  * Chronic pain patients\n  * Opioid use disorder\n  * Patient with intrauterine fetal demise\n  * Prisoners\\[","FEMALE","18 Years",{"count":55,"type":23},135,[57],"PHASE2","Needle phobia is a barrier for receiving appropriate care during pregnancy and can lead to complications of the mother and fetus that could easily be avoided. Needle phobia can affect routine prenatal care, increase the demand for general anesthesia during c-section, and increase post-op pain. During epidural placement, providers use local anesthetic in various methods to numb the area where the needle will be inserted. Pain from these anesthetic administrations can increase needle phobia and their side effects.\n\nOne use of local anesthetic is the lidocaine patch, and studies have shown it is effective in reducing pain level in patients \\[6, Firmani\\]. The transdermal lidocaine patch may lower the physical pain and mental effects of needle phobia in pregnant women and lower the side effects from that. Although lidocaine patch may take more time to numb the skin, a high number of expecting mothers will not require an epidural for labor analgesia right away. Therefore, administration of lidocaine patch might be an effective alternative.\n\nPregnant women needing epidural placement will be randomized into three groups, the lidocaine patch group, intradermal anesthetic group, or use of both to determine the effectiveness of the lidocaine patch compared to the intradermal administration.",[60],"Lidocaine Patch","2026-07-08",{"date":35,"type":36},{"date":64,"type":36},"2026-06-29",{"date":66,"type":23},"2029-01-31",{"name":42,"class":43},1,{"id":70,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":71,"targetDuration":4,"studyType":24,"phases":72,"briefSummary":27,"conditions":73,"keywords":74,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":79,"leadSponsor":80,"locationsCount":44},"100636542",{"count":22,"type":23},[26],[29],[31],"2026-07-01",{"date":77,"type":36},"2026-07-02",{"date":38,"type":36},{"date":40,"type":23},{"name":42,"class":43},{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":24,"phases":90,"briefSummary":92,"conditions":93,"keywords":98,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":68},"100585575","health-coaching-for-patients-with-cardiovascular-disease-100585575","NCT06904144","Health Coaching for Patients With Cardiovascular Disease","Health Coaching for Patients With Cardiovascular Disease: A Mixed-Methods Evaluation of the Impact on Patient Outcomes and Provider Satisfaction and Acceptability","Inclusion Criteria:\n\n* 18 years of age or older\n* diagnosis of coronary artery disease resulting in myocardial infarction and\u002For congestive heart failure\n* physical condition effectively managed by routine healthcare and not requiring urgent medical attention\n* ability to communicate in English\n* access to a working phone or computer and ability to communicate via phone or computer.\n\nExclusion Criteria:\n\n* Patients who have had chest coronary artery bypass surgery\n* Documented cognitive and\u002For major psychiatric disorders, including dementia, Alzheimer's, depression or anxiety uncontrolled by anxiolytic, anti-psychotic, and\u002For anti-depressants and\u002For PHQ-9 score 15-27 and GAD-7 score \\>15\n* current alcohol or drug dependency\n* resident of extended care\u002Fskilled facility\n* prisoners or ward of state.",{"count":89,"type":23},70,[91],"NA","For patients discharged with a diagnosis of cardiovascular disease coronary artery disease resulting in myocardial infarction and\u002For congestive heart failure, this study will evaluate if the addition of 12 virtual health coaching sessions over the course of 16 weeks will improve physiological, psychological, and social health outcomes, prove acceptable and satisfactory for these patients with CVD, decrease CVD-related questions and concerns sent to the provider via MyChart, and reduce hospital readmission rates over a 90-day period as compared to patients discharged with the same diagnosis who receive standard post-discharge care. The study will also evaluate the perceptions of physician and advanced practice providers related to the health coach as part of the interprofessional team and the amount of time spent addressing CVD-related patient questions and concerns via MyChart messages.",[94,95,96,97],"Congestive Heart Failure Treated","Myocardial Infarction (MI)","Coronary Artery Disease","Congestive Heart Failure Chronic",[99,100,101,102],"health coaching","coronary artery disease","congestive heart failure","myocardial infarction","NOT_YET_RECRUITING","2026-06-30",{"date":75,"type":36},{"date":107,"type":23},"2026-10-01",{"date":109,"type":23},"2028-10-01",{"name":42,"class":43},{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":24,"phases":120,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":68},"100609666","solving-stigma-through-pov-simulation-enhancing-pharmacist-empathy-based-practices-with-sickle-cell-disease-patients-100609666","NCT07217548","Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients","point of view","Inclusion Criteria:\n\n* Practicing healthcare professional OR student in a healthcare professional program\n* Ability to fill opioid prescriptions\n\nExclusion Criteria:\n\n* Not currently practicing or rotating in a clinical setting that fills opioid prescriptions",{"count":119,"type":23},200,[91],"Why This Research Matters (Significance)\n\n1 in 5 of the 50+ million people with chronic pain in the U.S. face stigma when using opioids, especially women and racial minorities. This stigma often comes from pharmacy staff treating chronic pain patients as drug seekers, who then refuse to fill the patient's script, and leave the patient in severe pain. The team has found that having pharmacists watch testimonial videos of sickle cell patients sharing their pain management struggles can help reduce these misconceptions. However, using point of view simulations could be even more effective in fostering empathy among pharmacists. The goal is to create an educational simulation that helps pharmacists better understand and manage pain in sickle cell patients, ultimately improving their care.\n\nWhat Makes This Research Unique (Innovation) Traditional methods to address biases in healthcare include watching patient testimonials or using expensive actors to play a standardized patient interaction to health professionals. This innovative point of view simulations engage participants' empathy more effectively by playing back what participants told the patient from the patient's point of view and are more accessible by having participants interact with the simulation on the computer any time and any place, rather than organizing a paid actor to visit the hospital. With advancements in artificial intelligence, we can create interactive simulations where virtual patients respond dynamically to questions, making the experience more realistic and impactful.\n\nHow Will the Researchers Conduct the Research (Approach)\n\nThe researchers will test if point of view simulations can reduce misconceptions among healthcare professionals and improve pain management for sickle cell patients. Here's the plan:\n\n1. Create and Implement the Simulation: Use it as part of the training for pharmacy and hospital staff, as well as nursing and pharmacy students.\n2. Survey Participants: Before and after the simulation, participants will take a survey to measure their misconceptions about opioid use.\n3. Follow-Up: Six months later, researchers will survey the participants' patients and their managers to see if there's been an improvement in the empathetic care the participants provided.",[123],"Stigma",[125,126],"pharmacists","PharmD students",{"date":75,"type":36},{"date":129,"type":23},"2026-09-01",{"date":131,"type":23},"2027-07-31",{"name":42,"class":43},{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":24,"phases":141,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":157,"leadSponsor":159,"locationsCount":68},"100645112","evaluating-the-effects-of-a-mindfulness-intervention-on-health-outcomes-in-individuals-with-hypertension-100645112","NCT07679984","Evaluating the Effects of a Mindfulness Intervention on Health Outcomes in Individuals With Hypertension","Inclusion Criteria:\n\n1. Age \\>18 years old.\n2. Established patient at OSU Family Medicine\n3. Diagnosis of primary essential hypertension\n4. Ability and willingness to participate in all Mindfulness in Motion (MIM) study activities.\n5. Ability and willingness to download MyCap, the smartphone app that securely links participant study responses to the REDCap study project.\n6. WiFi connectivity or LTE to allow use of MIM smartphone app and MyCap when not at OSU clinical site.\n\nExclusion Criteria:\n\n1. Inability to read and\u002For understand English (MIM intervention, study consent and questionnaires in English).\n2. Established mindfulness practice.\n3. Diagnosis of secondary hypertension with identifiable underlying causes including:\n\n   * Chronic kidney disease\n   * Renal artery stenosis\n   * Primary aldosteronism\n   * Cushing's syndrome\n   * Pheochromocytoma\n   * Obstructive sleep apnea\n   * Medication induced hypertension (e.g., steroids, NSAIDs)\n   * Pregnancy related hypertension\n4. Current severe alcohol or substance abuse disorder.\n5. Participants with documented cognitive disorder that limits the ability to independently participate in MIM program, read, understand, and\u002For complete the surveys; i.e. dementia, Alzheimer's or biological tests.\n6. Participants with major psychiatric disorders not controlled by medication or other psychiatric treatments.",{"count":140,"type":23},140,[91],"The purpose of this study is to evaluate the effectiveness of adding the Mindfulness in Motion (MIM) program to the usual primary care for people with high blood pressure. MIM is a facilitated, 8-week online program that teaches simple ways to manage stress using mindfulness practices. The program also includes the use of a companion smartphone app throughout the 12-month study period. In this study, we will compare people who receive their usual care and take part in the MIM program with those who receive usual care alone to see if it helps improve blood pressure, weight, stress, sleep, and overall well-being. Over 12 months, all participants will be asked to complete short questionnaires about stress, sleep, and resilience four times via a smartphone, tablet, or computer.",[144,145],"Hypertension","Essential (Primary) Hypertension",[147,148,149,150,151,152,153],"hypertension","primary care","mindfulness","stress","resilience","sleep","blood pressure","2026-06-26",{"date":75,"type":36},{"date":107,"type":23},{"date":158,"type":23},"2028-05-01",{"name":42,"class":43},{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":24,"phases":168,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":68},"100645264","examining-the-efficacy-of-short-term-intensive-ptsd-treatment-on-psychological-and-cognitive-impairment-symptoms-100645264","NCT07680517","Examining the Efficacy of Short-Term Intensive PTSD Treatment on Psychological and Cognitive Impairment Symptoms","Inclusion Criteria:\n\n-Treatment-seeking military personnel (i.e., any assigned or aligned JSOC personnel) who meet diagnostic criteria for PTSD or subthreshold PTSD (i.e., meeting diagnostic threshold for 3 of 4 symptom criteria who are (1) 18 years of age or older; (2) current diagnosis of PTSD or subthreshold PTSD (i.e. meeting diagnostic criteria for 3 of 4 symptom criteria, assessed using the DIAMOND); (3) current military personnel; (4) ability to speak and understand the English language; and (5) ability to complete the informed consent process\n\nExclusion Criteria:\n\n* (1) substance use disorder requiring medical management; (2) imminent suicide risk warranting inpatient hospitalization or suicide-focused treatment; and (3) impaired mental status that precludes the ability to provide informed consent (e.g., intoxication, psychosis, mania).",{"count":167,"type":23},120,[91],"Our long-term goal is to provide rapid and sustained reductions of trauma and cognitive-related symptoms among Special Operations personnel with PTSD or subthreshold PTSD. The primary objective of this project is to examine the effectiveness of massed PTSD treatment (i.e., CPT and EMDR) in \"real-world\" military settings. CPT and EMDR are both empirically supported psychotherapies for PTSD. To accomplish this objective, we will enroll military personnel meeting diagnostic criteria for PTSD or subthreshold PTSD (i.e., meeting threshold levels for 3 of 4 symptom criteria).",[171,172],"PTSD","Cognitive Performance",[171,174,175],"CPT","Military","2026-06-25",{"date":77,"type":36},{"date":179,"type":36},"2026-04-01",{"date":181,"type":23},"2028-08",{"name":42,"class":43},{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":24,"phases":193,"briefSummary":195,"conditions":196,"keywords":199,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":214},"100550351","phase-4-decide-a-comparative-effectiveness-trial-of-metformin-versus-insulin-for-the-treatment-of-gestational-diabetes-100550351","NCT06445946","DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","DECIDE: A Comparative Effectiveness Trial of Oral Metformin Versus Injectable Insulin for the Treatment of Gestational Diabetes","DECIDE","Inclusion Criteria:\n\n* Singleton gestation. Twin reduction to singleton, either spontaneously or therapeutically, is eligible if it occurred before 14 weeks gestational age.\n* Age 18 years or older\n* Gestational age at randomization between 20 0\u002F7 - 33 6\u002F7 weeks based on project gestational age.\n* GDM diagnosis less than or equal to 33 6\u002F7 weeks based on project gestational age.\n* Requires medication for glucose control defined as ≥ 30% elevated glucose values (either fasting or postprandial or both) prior to randomization per determination of the provider or documented in the medical record.\n* Patient willingness and ability to attend 2-year follow-up visit.\n\nExclusion criteria:\n\n* Renal disease (serum creatinine \\>1.3 mg\u002FdL) due to the potential impact of metformin on renal function.\n* Major structural malformation of the fetus.\n* Known fetal aneuploidy based on invasive testing or positive for aneuploidy on cell-free fetal DNA screening.\n* Contraindication to metformin or insulin, including: history of lactic acidosis, intractable nausea and vomiting, prior documented allergy and\u002For anaphylaxis.\n* For individuals with GDM diagnosed \\\u003C20 0\u002F7 weeks, documented A1c ≥\\>6.5% within prior 6 months.\n* Pregestational diabetes documented in the medical record or prior A1c\\>= 6.5%\n* Fasting hyperglycemia \\>115 mg\u002Fdl for ≥ 50% of fasting glucose values in the past week (due to the high risk of metformin failure with fasting hyperglycemia).\n* Enrolled in a trial that influences primary study outcomes (composite neonatal outcome at delivery or childhood body mass index at 2 years).\n* Prenatal care or delivery planned at a location where access to the complete electronic medical record will not be available to research staff.\n* Language barrier (appropriate translation resources unavailable at the site)\n* Participation in this trial in a previous pregnancy. Patients who were screened in a previous pregnancy, but not randomized, may be included.",{"count":192,"type":23},1572,[194],"PHASE4","This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin.\n\nThis study will determine if metformin is not inferior to insulin in reducing adverse pregnancy outcomes, is comparably safe for exposed individuals and children, and if patient-reported factors, including facilitators of and barriers to use, differ between metformin and insulin. A total of 1,572 pregnant individuals with GDM who need pharmacotherapy will be recruited at 20 U.S. sites using consistent treatment criteria to metformin versus insulin. Participants and their children will be followed through delivery to two years postpartum.",[197,198],"Gestational Diabetes Mellitus","Pregnancy, High Risk",[200,201,202,203,204,205,206],"Insulin","Pregnancy","Glycemic control","Metformin","Gestational diabetes","Diabetes","Adverse pregnancy outcomes","2026-06-24",{"date":176,"type":36},{"date":210,"type":36},"2024-08-01",{"date":212,"type":23},"2030-12",{"name":42,"class":43},24,{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":24,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":68},"100538044","enhancing-the-effectiveness-of-prolonged-exposure-among-suicidal-individuals-with-ptsd-100538044","NCT06285708","Enhancing the Effectiveness of Prolonged Exposure Among Suicidal Individuals With PTSD","Inclusion Criteria:\n\n* Current diagnosis of PTSD or subthreshold PTSD; ability to speak and understand the English language; and ability to complete the informed consent process.\n\nExclusion Criteria:\n\n* Substance use disorder requiring medical management; imminent suicide risk warranting inpatient hospitalization or suicide-focused treatment; and impaired mental status that precludes the ability to provide informed consent (e.g., intoxication, psychosis, mania).",{"count":222,"type":23},100,[91],"The long-term goal of this study is to reduce suicidal thoughts and behaviors among treatment-seeking individuals who also have posttraumatic stress disorder (PTSD). Prolonged exposure (PE) and crisis response plan (CRP) have demonstrated empirical support for reducing suicide attempts as compared to treatment as usual. However, no studies to date have assessed their effectiveness when used in combination. In light of this knowledge gap, the primary objective of this study will be to test the effectiveness of PE augmented with CRP as compared to PE with care as usual (self-guided treatment plan), an active comparator, for the reduction of suicide ideations and attempts for individuals with comorbid PTSD.",[171,226,227,228],"Suicidal Ideation","Suicide, Attempted","Trauma, Psychological",{"date":64,"type":36},{"date":231,"type":36},"2024-02-26",{"date":233,"type":23},"2027-06",{"name":42,"class":43},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":24,"phases":244,"briefSummary":245,"conditions":246,"keywords":250,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":68},"100490156","successfully-achieving-and-maintaining-euglycemia-during-pregnancy-for-type-2-diabetes-through-technology-and-coaching-100490156","NCT05662462","Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching","ACHIEVE: Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching","Inclusion Criteria:\n\n1. pregnant individuals age ≥18 years;\n2. ≤20 weeks of gestation (specifically, \\\u003C20+6 weeks);\n3. diagnosis of pregestational T2D and A1c ≥6.5% at the time of study enrollment;\n4. Medicaid insurance;\n5. English or Spanish speaking;\n6. cognitively able to complete the study requirements;\n7. consent to all study activities;\n8. accessible for participation in study activities;\n9. use a smartphone with internet access;\n\nParticipants must also consent to the study team abstracting information from their electronic health records (EHRs), using CGM for glucose monitoring if randomized to the intervention group, tracking the participants' clinic, hospital, and emergency room visits during the study period, as well as tracking the number of times the participants use the ACHIEVE mobile health (mHealth) application (app), including what activities are used in the mobile application (e.g., recording blood glucose, scheduling appointments, messaging their healthcare providers, accessing educational resources).",{"count":243,"type":23},124,[91],"The ACHIEVE RCT will measure the effect of the intervention (mHealth app with CGM, provider dashboard, and care team coaching) compared to current standard care (prenatal visits, self-monitored blood glucose, and certified diabetes care and education specialist) on achieving glycemic control (hemoglobin A1c \\\u003C6.5% in the third trimester). We hypothesize a 25% absolute increase in the proportion of participants in the intervention group who will meet the target hemoglobin A1c \\\u003C6.5% in the third trimester compared to the standard care group",[247,248,249,198],"Pre-Gestational Diabetes","Type2diabetes","Pregnancy in Diabetic",[251,201,252,253,254,255,202],"mHealth","Type 2 diabetes","Continuous glucose monitoring","Mobile application","Medicaid",{"date":64,"type":36},{"date":258,"type":36},"2024-07-11",{"date":260,"type":23},"2029-03",{"name":42,"class":43},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":269,"enrollmentInfo":270,"targetDuration":4,"studyType":24,"phases":272,"briefSummary":273,"conditions":274,"keywords":277,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":68},"100521924","ketone-conferred-resiliency-against-sleep-restriction-with-nutritional-intervention-100521924","NCT06075914","Ketone Conferred Resiliency Against Sleep Restriction With Nutritional Intervention.","Strategies to Augment Ketosis: Ketone Conferred Resiliency Against Sleep Restriction With Nutritional Intervention (STAK - Sleep + Feed)","Inclusion Criteria:\n\n* Healthy, 18-40 years old.\n* BMI: 20-35 kg\u002Fm2\n* Sleep at least 7h per night.\n* Willing to participate in \\~9-weeks of testing and provided food.\n* Willing to adhere to all study procedures.\n\nExclusion Criteria:\n\n* \\\u003C18 or \\>40 years of age\n* \\>35 body mass index (BMI).\n* Diagnosed sleeping disorders (i.e., sleep apnea, insomnia).\n* Gastrointestinal disorders or food allergies that would interfere with consuming the study supplements.\n* Drink alcohol in excess of 3 drinks\u002Fday or 14 drinks\u002Fweek\n* Have any conditions or contraindications to blood draws.\n* Have been diagnosed with diabetes, liver, kidney, or other metabolic or endocrine dysfunction, or use diabetic medications other than metformin\n* Currently consume a low carbohydrate or ketogenic diet or have done so in the last 3 months\n* Have experienced weight loss of \\>10% of your body weight within the last 6 months\n* Are pregnant, lactating, or planning on becoming pregnant during the study\n* Have any major psychiatric disorders (e.g., schizophrenia, bipolar disorder)","40 Years",{"count":271,"type":23},60,[91],"Sleep deprivation is a major problem in military populations. Some major consequences of sleep loss are inability to concentrate, poor work efficiency, and increase in errors during daily tasks. Ketogenic supplementation is speculated to alleviate some sleep deprivation issues via action of ketones. Ketones are small molecules that appear in the blood when following a ketogenic diet or consuming ketone supplements. The goal of this project is to find out if diet and\u002For ketones can improve sleep deprivation detriments over 5 days of sleep restriction (-50% from habitual sleep).",[275,276],"Sleep Deprivation","Nutritional Intervention",[278,279,280,281],"Ketogenic Diet","Mediterranean Diet","Ketone Esters","Placebo","2026-06-23",{"date":207,"type":36},{"date":285,"type":36},"2023-05-01",{"date":287,"type":23},"2027-02",{"name":42,"class":43},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":52,"minAge":269,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":24,"phases":299,"briefSummary":300,"conditions":301,"keywords":304,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":68},"100639154","evaluation-of-the-effects-of-lifestyle-medicine-and-mindfulness-based-group-medical-visits-on-stress-microbiome-and-quality-of-life-in-women-experiencing-perimenopause-and-menopause-100639154","NCT07619352","Evaluation of the Effects of Lifestyle Medicine and Mindfulness-based Group Medical Visits on Stress, Microbiome, and Quality of Life in Women Experiencing Perimenopause and Menopause","A Pilot Study to Evaluate the Effects of Lifestyle Medicine and Mindfulness-based Group Medical Visits on Stress, Microbiome, and Quality of Life in Women Experiencing Perimenopause and Menopause","Inclusion Criteria:\n\n1. Biological female.\n2. Age 40 to 60.\n3. Irregular menstruation for 3 months and experiencing perimenopause or menopause as determined by reporting at least one symptom on the Menopause Quality of Life Questionnaire (MENQOL).\n4. Ability to attend group medical visits monthly, in-person for 8 months, at The Ohio State University Center for Integrative Health as well as the baseline and end of study visit.\n5. Ability to participate in the Mindfulness in Motion (MIM) study activities.\n6. Ability and willingness to download MyCap, the smartphone app that securely links participant study responses to the REDCap study project.\n7. WiFi connectivity or LTE to allow use of MyCap when not at OSU study site\n\nExclusion Criteria:\n\n1. Participants with surgically induced menopause, e.g., hysterectomy, oophorectomy.\n2. Currently receiving or planning to receive hormone therapy for perimenopausal or menopausal symptoms.\n3. Currently taking or planning to take hormonal contraceptives.\n4. Currently taking or planning to take hormone altering medications; i.e. Taxol.\n5. Currently taking probiotics, Siberian rhubarb (Rheum rhaponticum), Black cohosh (Actaea racemosa), Chaste tree berry (Vitex agnus-castus).\n6. Inability to read and\u002For understand English (consent and questionnaires in English).\n7. Current severe alcohol or substance abuse disorder.\n8. Participants with documented cognitive disorder that limits the ability to independently read, understand, and\u002For complete the survey or biological; i.e. dementia, Alzheimer's or biological tests.\n9. Participants with major psychiatric disorders not controlled by medication or other psychiatric treatments.","60 Years",{"count":298,"type":23},40,[91],"While perimenopause and menopause are natural biological transitions, women may experience a wide range of physical, emotional, and cognitive symptoms. Although pharmacological options for symptom relief are available, these options may not be acceptable or suitable for all women. Integrative approaches for symptom relief, offered through group medical visits, may complement traditional therapies by increasing access to providers, allowing more time for focused education, and fostering supportive discussions with other women experiencing similar symptoms of perimenopause or menopause.\n\nThe purpose of this study is to assess the effectiveness of eight monthly group medical visits that incorporate individual physical assessments, focused education on the foundational elements of Lifestyle Medicine relative to health and well-being, mindfulness practices, and community-building discussions with women experiencing perimenopause or menopause. Individual outcomes, obtained before the group medical visits begin, at each monthly group medical visit, and four months after the group medical visits are completed, will include measures of participants' perimenopause or menopause symptoms, stress, inflammation, microbiome (good bacteria in the body), height\u002Fweight, body mass index (BMI), systolic and diastolic blood pressure, and self-reported perceptions of physical, mental, and social health.\n\nEach 120-minute monthly group medical visit, led by a specially trained nurse practitioner and a mindfulness instructor, will include a brief physical assessment, educational discussions related to menopause and lifestyle medicine, experiential mindfulness practices, and the development of individual health and well-being goals.",[302,303],"Perimenopause","Menopause",[305,306,150,307,308,309],"perimenopause","menopause","microbiome","quality of life","women","2026-06-18",{"date":282,"type":36},{"date":313,"type":23},"2026-08-01",{"date":315,"type":23},"2028-08-30",{"name":42,"class":43},{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":24,"phases":326,"briefSummary":327,"conditions":328,"keywords":331,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":339,"leadSponsor":341,"locationsCount":68},"100636063","nourish---a-healthcare-community-partnership-to-improve-nutrition-for-optimal-glycemic-control-and-pregnancy-outcomes-with-pregestational-diabetes-100636063","NCT07560813","NOURISH - A Healthcare-community Partnership to Improve Nutrition for Optimal Glycemic Control and Pregnancy Outcomes With Pregestational Diabetes","NOURISH","Inclusion criteria:\n\n* Pregnant with singleton or twin pregnancy\n* Gestational age \\>8+0 to ≤22+6 weeks at enrollment by project EDD\n* Age ≥ 18 years.\n* Type 1 or 2 diabetes.\n* Screen positive for food insecurity based on answering \"Often\" or \"Sometimes\" true to either of the two questions on the USDA Hunger Vital Sign screening questions (within 12 months of enrolling in prenatal care).\n* English or Spanish speaking.\n* Willing to participate in Mid-Ohio Farmacy program and able to provide a home address to which food delivery can be provided by the Mid-Ohio Food Collective.\n* Hemoglobin A1c criteria:\n\n  * If not taking glucagon-line peptide-1 (GLP-1) or sodium-glucose co-transporter 2 (SGLT2) medication within 12 months of enrolling in prenatal care, A1c ≥6.5% during this time period.\n  * If taking GLP-1 or SGLT2 medication within 12 months of enrolling in prenatal care, A1c≥6.5% during the 12 months prior to initiation of these medications.\n\nExclusion Criteria\n\n* Involuntarily confined or detained.\n* Considered as having a diminished decision-making capacity.",{"count":325,"type":23},174,[91],"Nutrition insecurity (inclusive of food insecurity + poor diet quality) is a fundamental social need that must be addressed to improve treatment and health outcomes for high-risk pregnant women with pregestational type 1 and 2 diabetes, poor glucose control, and food insecurity for whom a healthy diet is critical. The NOURISH trial will provide evidence of a scalable, integrated, and theory-based healthcare-community partnership that includes weekly nutritious produce home delivery, monthly clinic-integrated diabetes, nutrition, and culinary group education, and continuous social needs assessment and support to improve glucose control and pregnancy outcomes. Given the increasing burden and devasting consequences of nutrition insecurity among high-risk pregnant women with diabetes and unmet social needs, NOURISH-an innovative and sustainable healthcare-community partnership-will have significant public health benefit.",[329,330,198],"Type 2 Diabetes","Type 1 Diabetes",[201,330,329,332,333,334],"food insecurity","nutrition insecurity","social determinants of health","2026-06-17",{"date":337,"type":36},"2026-06-22",{"date":75,"type":23},{"date":340,"type":23},"2030-06-30",{"name":42,"class":43},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":24,"phases":351,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":68},"100571302","brief-digitally-enhanced-intervention-for-reducing-alcohol-use-during-moud-100571302","NCT06718491","Brief Digitally-Enhanced Intervention for Reducing Alcohol Use During MOUD","Brief Digitally-Enhanced Intervention for Managing Emotional Pain and Reducing Alcohol Use During Medication for OUD","Inclusion Criteria:\n\n* Enrolled in outpatient medication for opioid use disorder (MOUD) program (within the past month)\n* Heavy alcohol user defined using the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria (i.e., consume 8+\u002F15+ drinks per week \\[women\u002Fmen\\] with at least two binge episodes \\[4\u002F5+ drinks for women\u002Fmen in a 2 hour period\\] in the past month)\n* Elevated psychological distress defined as a total score of \\> 12 on the Kessler Psychological Distress Scale (K10; 0 to 40 range)\n* 18 years of age or older\n* Can read and comprehend English\n\nExclusion Criteria:\n\n* Do not pass the informed decision-making capacity screener, suggesting cognitive impairment or an inability to provide informed consent\n* Presence of a psychiatric or medical condition that would prevent them from providing informed consent or participating in the treatments (e.g., psychosis, mania, acute intoxication)\n* Current comorbid moderate to severe substance use disorder other than alcohol and opioids\n* Limited or no access to a smart phone that is compatible with the mobile application\n* Participation in Phase One\n* Possibility of being pregnant (by self-report)\n* Current suicidal or homicidal intent indicating a need for immediate hospitalization or treatment as determined by clinical interviewer",{"count":350,"type":23},80,[91],"The goal of this clinical trial is to reduce heavy drinking and enhance medication for opioid use disorder (MOUD) outcomes in individuals receiving MOUD. The main questions it aims to answer are:\n\n* Does the brief, digitally-enhanced, virtual psychotherapeutic intervention, called Managing Physical Reactions to Overwhelming Emotions (IMPROVE), impact daily alcohol use and MOUD adherence?\n* Does the intervention change self-report and physiological responses to intolerance to uncertainty and anxiety sensitivity?\n\nResearchers will compare IMPROVE to a control intervention (health education treatment) to see if IMPROVE impacts daily alcohol use and MOUD adherence.\n\nParticipants will:\n\n* Complete a baseline electroencephalography (EEG) and self-report questionnaires.\n* Complete three one-hour intervention sessions (IMPROVE or control) each one week a part.\n* Complete a post-intervention EEG and self-report questionnaires.\n* Complete five ecological momentary assessment (EMA) surveys a day for 21 days.\n* Complete self-report questionnaires one-month after their last intervention session.",[354],"Opioid Use Disorder",[356,357,358,359],"Medications for Opioid Use Disorder","Heavy Alcohol Use","Ecological Momentary Assessments","Electroencephalography",{"date":337,"type":36},{"date":362,"type":36},"2025-08-01",{"date":364,"type":23},"2027-07",{"name":42,"class":43},{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":374,"phases":4,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":68},"100641522","evaluating-the-association-of-force-feedback-with-outcomes-after-lung-resection-using-the-da-vinci-multiport-system-100641522","NCT07660900","Evaluating the Association of Force Feedback With Outcomes After Lung Resection Using the da Vinci Multiport System","Inclusion Criteria:\n\n* Ages 18 years or older\n* Undergoing robotic-assisted anatomic lung resection (lobectomy or segmentectomy) at The Ohio State University Wexner Medical Center\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Subject is pregnant or suspected to be pregnant or breastfeeding\n* ECOG Performance status \\> 2\n* Do not qualify for ERAS protocol\n* Undergoing an emergent procedure\n* Undergoing non-anatomic lung resection\n* Undergoing pneumonectomy\n* Previous ipsilateral thoracic surgery (open, video-assisted thoracoscopic or robotic)\n* Planned to undergo major concomitant surgery for the treatment of a different medical condition than was originally planned\n* Non-English speaking",{"count":373,"type":23},270,"OBSERVATIONAL","The purpose of this research is to study patient outcomes based on the use of Force Feedback instruments during robotic-assisted lung resection. Force Feedback technology describes the physical forces a surgeon senses when pushing and pulling structures inside the body during robotic-assisted surgery.",[377,378,379],"Lobectomy","Segmentectomy","Force Measurement","2026-06-16",{"date":337,"type":36},{"date":383,"type":36},"2025-09-05",{"date":385,"type":23},"2027-12-31",{"name":42,"class":43},{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":18,"minAge":394,"maxAge":395,"enrollmentInfo":396,"targetDuration":4,"studyType":24,"phases":397,"briefSummary":398,"conditions":399,"keywords":402,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":412,"locationsCount":68},"100630651","phase-2-metric-optimized-spectacle-prescriptions-for-children-with-down-syndrome-100630651","NCT07490444","Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome","Metric-derived Corrections Versus Clinically-derived Corrections for Children With Down Syndrome","Inclusion Criteria:\n\n* Down syndrome\n* Age 5 to 12 years\n* Ability to sit for study measures\n* Able to be dilated\n\nExclusion Criteria:\n\n* Nystagmus\n* History of Ocular or Refractive Surgery\n* Corneal or lenticular opacities\n* Ocular disease\n* Anisometropic or strabismic amblyopia\n* Contact allergy to aluminum","5 Years","12 Years",{"count":214,"type":23},[57],"This study seeks to determine whether glasses prescriptions determined from computer analysis of detailed images of the eyes provide better vision outcomes for children with Down syndrome than prescriptions determined using routine clinical methods.",[400,401],"Refractive Error Correction","Visual Acuity",[403,404,405,406,407],"Down syndrome","Children","Glasses","Spectacles","Vision",{"date":310,"type":36},{"date":410,"type":36},"2026-05-26",{"date":158,"type":23},{"name":42,"class":43},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":24,"phases":421,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":68},"100538200","spinal-cord-stimulation-and-small-fiber-peripheral-neuropathy-100538200","NCT06287736","Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy","A Novel Neuromodulation Approach to Target Small Fiber Neuropathy Early in Diabetes and Measure Functional Recovery","Inclusion Criteria:\n\n* Over 18 years old\n* Diagnosis of diabetic peripheral neuropathy refractory to treatment with gabapentin or pregabalin and at least 1 other class of analgesic\n* Diagnosis of medically refractory pain secondary to diabetic neuropathy\n* Presence of pain for 12 months\n* Lower limb pain intensity score ≥4 on a visual analog scale\n* DN4 ≥4\n* Pass pre-operative neuropsychological assessment (surgical group only)\n* Capable of providing informed consent\n\nExclusion Criteria:\n\n* Severe medical comorbidities that, in the opinion of the surgeon, exclude the patient from surgical intervention\n* Spinal disease with severe spinal stenosis or spinal cord compression in the region of the proposed spinal cord stimulator lead placement\n* Coagulopathy that cannot be corrected\n* Unable to discontinue blood thinning medications\n* Hemoglobin A1c level greater than 10\n* Presence of systemic infection\n* Pregnancy",{"count":271,"type":23},[91],"This is a prospective randomized control trial. Participants enrolled into the study will be randomized into one of three groups, two of which are treatment groups and the third is a control group. A time course of measurements before and after spinal cord stimulation (SCS) treatment (where applicable) will assess pain, DPN severity, small fiber nerve activity, and metabolic health markers.",[424],"Diabetic Peripheral Neuropathy","2026-06-15",{"date":335,"type":36},{"date":428,"type":36},"2024-04-17",{"date":430,"type":23},"2029-12-31",{"name":42,"class":43},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":24,"phases":442,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":452,"locationsCount":453},"100552751","phase-4-pancreatic-enzyme-replacement-therapy-for-acute-pancreatitis-associated-exocrine-pancreatic-insufficiency-100552751","NCT06477159","Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency","Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency: the PERT-AP Trial","PERT-AP","Inclusion Criteria:\n\n1. Adult patients of age 18 or older, able to provide informed consent and follow all study procedures.\n2. Stable outpatient up to 12 months following an acute pancreatitis episode and has EPI based on an FE-1 \\\u003C 200 µg\u002Fg stool obtained within 3 months prior to baseline assessment (Visit 2).\n3. Score of equal or greater 0.6 on the EPI symptom tracker at baseline Visit 2.\n4. Must be off PERT (including prescription and non-prescription enzymes) for 7 days prior to baseline Visit 2.\n5. Must have fully completed the terminal intervention for necrotizing pancreatitis (surgical or endoscopic necrosectomy or percutaneous drainage).\n6. Have a Body Weight between 40 and 120 kg (amounts to 600-1800 LU\u002Fmeal pancrelipase starting dose of pancrelipase).\n7. Women of childbearing potential must have a negative urine pregnancy test at Study Day 1 and practicing at least one protocol specified method of birth control (Section 5.2.4), starting at Study Day 1 through 30 days after last dose of pancrelipase.\n8. Females of non-childbearing potential (either postmenopausal or permanently surgically sterile as defined:\n\n   * Age \\> 55 years with no menses for 12 or more months without an alternative medical cause.\n   * Age ≤ 55 years with no menses for 12 or more months without an alternative medical cause AND an FSH level \\> 40 IU\u002FL.\n\nOR\n\n* Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).\n\ndo not require pregnancy testing.\n\nExclusion Criteria:\n\n1. Acute pancreatitis episode due to a pancreatic cystic neoplasm, trauma, or surgery. Post-ERCP acute pancreatitis patients can be enrolled.\n2. History of definite chronic pancreatitis defined by APA Chronic Pancreatitis Guideline.1\n3. Pancreas malignancy or other active malignancies requiring systemic treatment; treated basal cell carcinoma, and treated in-situ cervical cancer can be included.\n4. Enteropathies, and gastroenteritis that may affect FE-1 levels, e.g., Inflammatory bowel disease, Celiac Disease, viral-, bacterial-, fungal-, or parasitic gastroenteritis.\n5. Gastroparesis.\n6. Confirmed or suspected cystic tumor associated with main pancreatic duct dilation or believed to be the cause of AP (in the site-PI's judgment).\n7. Prior pancreatic surgery or GI tract surgery affecting the upper GI tract including but not limited to gastric bypass surgery, total pancreatectomy.\n8. Pregnancy or breast feeding.\n9. Patients with life expectancy of less than 6 months due to advanced chronic conditions, such as congestive heart failure or chronic obstructive pulmonary disease, or other conditions which preclude study participation by judgement of the investigator.\n10. Incarcerated individuals",{"count":441,"type":23},30,[194],"This study aims to evaluate if a 6-month course of pancrelipase (CREON) treatment improves symptoms of exocrine pancreatic insufficiency (EPI) after an attack of acute pancreatitis. Diagnosis of EPI is measured by a fecal elastase value of \\\u003C200, and patients must have a qualifying symptom burden based on the EPI symptom tracker survey. Blood and stool will be analyzed as part of this study, and other surveys of health status will be used to track improvement of symptoms.",[445],"Exocrine Pancreatic Insufficiency","2026-06-08",{"date":448,"type":36},"2026-06-10",{"date":450,"type":36},"2024-02-01",{"date":385,"type":23},{"name":42,"class":43},6,{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":461,"enrollmentInfo":462,"targetDuration":4,"studyType":24,"phases":464,"briefSummary":465,"conditions":466,"keywords":468,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":475,"leadSponsor":477,"locationsCount":68},"100642825","fermented-foods-and-bowel-health-in-sci-100642825","NCT07640152","Fermented Foods and Bowel Health in SCI","High Fermented Food Intake to Improve Gut Microbiome and Bowel Dysfunction in Individuals With SCI","Inclusion Criteria:\n\n* Adults aged 18-70 years\n* At least 1 year post-onset of spinal cord injury, consistent with chronic spinal cord injury\n* Traumatic spinal cord injury involving cervical or thoracic levels\n* American Spinal Injury Association Impairment Scale classification A-D\n* Medically stable, with no recent hospitalizations or acute illnesses\n* Able to safely consume study foods, including fermented and control food products\n* Experiencing neurogenic bowel dysfunction, defined by at least one of the following:\n\n  1. Three or fewer bowel movements per week\n  2. More than 60 minutes required per bowel care routine\n  3. Symptoms of incomplete evacuation\n  4. Abdominal distension\n  5. Fecal incontinence\n* Established and stable bowel program, defined as a consistent individualized routine of timing, frequency, and evacuation methods that has remained unchanged for at least 4 weeks before enrollment\n\nExclusion Criteria:\n\n* Antibiotic use within the past 4 weeks\n* Active gastrointestinal disease, including Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal obstruction\n* Current intake of probiotics or fermented foods exceeding 3 servings per day\n* Pregnancy or breastfeeding\n* Recent major bowel surgery within the past 12 weeks\n* Unresolved fecal impaction\n* Unstable bowel regimen that could interfere with accurate motility assessment\n* Inability to safely undergo Sitz marker testing, including any of the following:\n\n  1. Inability to swallow the capsule\n  2. Pregnancy, due to radiation exposure\n  3. Contraindication to abdominal X-ray procedures","70 Years",{"count":463,"type":23},44,[91],"The goal of this clinical trial is to learn whether consuming a high fermented food diet improves bowel function and gut health in adults with chronic spinal cord injury (SCI). The study will also evaluate the feasibility and tolerability of consuming fermented foods daily for 10 weeks. The main questions it aims to answer are:\n\n1. Does a high fermented food diet improve neurogenic bowel dysfunction symptoms and colonic transit in adults with SCI?\n2. Does fermented food intake change gut microbiome composition, short-chain fatty acid production, and intestinal inflammation?\n\nResearchers will compare a high fermented food diet to a control diet to evaluate effects on bowel health and gut microbiome outcomes.\n\nParticipants will:\n\n* Consume study foods daily for 10 weeks\n* Attend 2 in-person study visits\n* Collect stool samples at home and ship them overnight to the research team using provided collection kits and prepaid shipping materials\n* Complete bowel health questionnaires and dietary recalls\n* Undergo Sitz marker testing with abdominal X-rays to assess colonic transit\n* Participate in biweekly monitoring contacts throughout the study period",[467],"Spinal Cord Injury",[469,470,471],"gut microbiome","bowel dysfunction","fermented food","2026-06-05",{"date":448,"type":36},{"date":313,"type":23},{"date":476,"type":23},"2029-07-31",{"name":42,"class":43},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":485,"enrollmentInfo":486,"targetDuration":4,"studyType":24,"phases":487,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":68},"100605481","nutrition-supplement-for-cystic-fibrosis-100605481","NCT07163078","Nutrition Supplement for Cystic Fibrosis","A Medical Nutrition Supplement for Cystic Fibrosis","Inclusion Criteria:\n\n* Diagnosed with cystic fibrosis\n* Diagnosed with exocrine pancreatic insufficiency\n* 18 years old or older\n* Currently on modulator\n* Normal liver enzyme labs\n\nExclusion Criteria: :\n\n* Non-English-speaking participants\n* Acute health crisis\n* Persistent elevation of liver enzymes \\>6 months (E2) (ALT \\>80 U\u002FL)\n* History of liver abnormalities\n* If patients are currently taking Category A or Category B in the LiverTox categorization system\n* Recent vitamin D supplementation of 30 mcg\u002Fday or higher, vitamin E supplements of 200 IU\u002Fday or higher, or copper at 2 mg\u002Fday or higher\n* Any other concern by investigator that the subject is inappropriate for inclusion\n* Patients who is on a reduced dose of a CFTR modulator\n* Patients on azole antifungals (voriconazole, itraconazole, posaconzole, \\>7 days of fluconazole, etc.).\n* Patients who binge drink EtOH - for men more than 2 drinks\u002Fday, for women more than 1 drink\u002F day\n* Patients that are on other medications that are sensitive CYP3A4 substrates - such as tacrolimus for example\n* Patients on sensitive CYP3A4 substrates including but not limited to tacrolimus, sirolimus, and cyclosporine","50 Years",{"count":271,"type":23},[91],"The goal of this study is to learn if one nutrition supplement formula works better than a different formula in adults with cystic fibrosis. The main question being addressed is: Will certain atypical versions of certain nutrients outperform typical versions of these nutrients? This will be determined by examining blood measures of nutrient levels and\u002For indications of nutrient function indicators pre- and post-intervention. Participants will take the supplements for 6 weeks with a blood draw before and after that time.",[490],"Cystic Fibrosis (CF)",[492,493,494,495],"Cystic Fibrosis","Vitamins","Copper","Choline",{"date":497,"type":36},"2026-06-09",{"date":499,"type":23},"2026-06",{"date":501,"type":23},"2027-01",{"name":42,"class":43},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":24,"phases":513,"briefSummary":514,"conditions":515,"keywords":519,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":524,"startDateStruct":525,"completionDateStruct":526,"leadSponsor":528,"locationsCount":529},"100536174","better-birth-outcomes-through-technology-education-and-reporting-100536174","NCT06261398","Better Birth Outcomes Through Technology, Education, and Reporting","Better Birth Outcomes and Experiences Through Technology, Education, and Reporting (BETTER)","BETTER","Inclusion Criteria\n\n* Less than 20 weeks and 6 days pregnant upon enrollment\n* At least 18 years of age\n* Receiving obstetric care at OSU McCampbell Hall or OSU Outpatient Care East\n* Singleton pregnancy and fetus with a heartbeat\n* English speaking\n* Able to receive text messages\n\nExclusion Criteria\n\n* Has a significant medical condition (eg sickle cell disease) that is a cause of anemia\n* Has a plan for transfusion during pregnancy",{"count":512,"type":23},550,[91],"This is a pragmatic randomized control trial to evaluate the BETTER intervention compared to standard obstetrical care (control) to determine whether it helps to reduce maternal anemia and other adverse pregnancy outcomes. The BETTER intervention includes one motivational interviewing session and bi-weekly text messages to encourage patients to connect with resources that address their social needs, including housing, food, and transportation. Quantitative data will be used to study participant outcomes, including surveys, and electronic health record data.",[201,516,517,518],"Maternal Anemia","Pre-Term Birth","Hypertensive Disorders",[520,201,521,522,523],"Social Determinants of Health (SDoH)","Patient portals","Patient engagement","Disparities",{"date":497,"type":36},{"date":231,"type":36},{"date":527,"type":23},"2028-03",{"name":42,"class":43},3,{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":24,"phases":538,"briefSummary":539,"conditions":540,"keywords":543,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":551,"completionDateStruct":552,"leadSponsor":554,"locationsCount":4},"100637798","effectiveness-of-a-sound-bowl-meditation-on-caregiver-stress-and-anxiety-100637798","NCT07626320","Effectiveness of a Sound Bowl Meditation on Caregiver Stress and Anxiety","Effectiveness of a Sound Bowl Meditation on Caregiver Stress and Anxiety: A Pilot Study","Inclusion Criteria:\n\n1. Adults age 18 years and older\n2. Primary, unpaid caregiver of a family member (spouse, sibling, parent, child, etc.) or an unrelated adult (friend) who is chronically ill and\u002For disabled\n3. Primary, unpaid caregiver has provided care to family member or an unrelated adult for a minimum of six months\n4. Normal hearing capacity with or without corrective hearing aids\n5. Availability and willingness to participate in the six week sound bowl meditation intervention\n6. Access to a smartphone or personal electronic tablet with adequate WiFi access and a personal email\n7. Willingness and ability to download the MyCap app to complete study surveys\n\nExclusion Criteria:\n\n1. Professional and\u002For paid caregivers\n2. Inability to read and\u002For understand English (consent, study instructions, and questionnaires in English)",{"count":298,"type":23},[91],"Being a primary caregiver for a family member or friend can be physically and emotionally demanding leaving little time for the unpaid caregiver's professional pursuits, personal appointments, and self-care. Primary caregivers are often overwhelmed, and experience stress, anxiety, depression, and sleep disturbances. Passive activities that require no physical or mental exertion may provide support and can help improve overall well-being. Sounds from crystal sound bowls and other instruments combined with guided meditations have been found to promote relaxation and to reduce stress and anxiety. Participants can sit in a chair or lie on a yoga mat, supported by pillows and blankets, to enhance comfort and rest. Eye masks can also be used to minimize light and promote peacefulness. The purpose of this study is to assess if a weekly Sound Bowl Meditation, offered over the course of 6 weeks and provided by a certified Sound Bowl practitioner, can help decrease caregiver stress and anxiety related to the role as a primary caregiver.",[541,542],"Stress","Anxiety",[544,545,546,547,548],"caregiver","family caregiver","caregiver stress","anxiety","caregiver anxiety","2026-06-03",{"date":472,"type":36},{"date":107,"type":23},{"date":553,"type":23},"2027-06-01",{"name":42,"class":43},{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":561,"enrollmentInfo":562,"targetDuration":4,"studyType":24,"phases":564,"briefSummary":565,"conditions":566,"keywords":568,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":68},"100637097","effect-of-fixation-training-with-colored-light-targets-on-traumatic-brain-injury-associated-photophobia-100637097","NCT07606300","Effect of Fixation Training With Colored Light Targets on Traumatic Brain Injury-Associated Photophobia","Inclusion Criteria:\n\n* 18 to 80 years old and subjects able to consent for themselves\n* Completion of first session in entirety (participants who cannot complete the entire first visit will be considered as a screen fail)\n* Best-corrected visual acuity of at least 20\u002F32 in both the right and left eyes, and 20\u002F25 using both eyes\n* Prior head injury with current photophobia - A mild or moderate TBI occurring at least 3 months prior to visit, verified by a score of 2, 3 or 4 on OSU-TBI survey, and participant reports having experienced greater light sensitivity since their head injury\n\nExclusion Criteria:\n\n* Pregnancy or suspected pregnancy - based on self-report\n* Previous history of neurodegenerative disease (e.g. Alzheimer's, Parkinson's, multiple sclerosis, myasthenia gravis, seizures)\n* History of pathology of the retina and optic nerve (includes retinal tears, diabetic retinopathy, glaucoma, macular degeneration, optic nerve atrophy)\n* Currently on cholinergic medications, which affect pupil responses\n* Prior participation in fixation training sessions within the past 2 years\n* Experiencing a migraine during visit\n* Prior history of severe TBI (score of 5 or 6 on OSU-TBI survey)","80 Years",{"count":563,"type":23},20,[91],"Many people develop intolerance to light after a head injury, leading to ambient light levels causing discomfort. We do not fully understand why this occurs and how it should be treated. A growing number of clinicians have reported improvement in TBI related symptoms reported by patients that undergo daily fixation training with a dim light target. While fixation training using various colored light targets is reported, blue light targets specifically appear to be used in this patient population more often than other light target colors. However, the effectiveness of this approach has yet to be assessed in a well-controlled clinical study. In this work, we will recruit individuals who had a recent brain injury and developed increased light sensitivity. Participants will be divided into two groups: one that first uses daily 20 minute sessions for 12 weeks with the at-home fixation device set to display a blue light target; and another that will undergo similar sessions for 12 weeks using a red light target. Every 6 weeks, masked examiners will measure how well participants can read letters on an eye chart, record pupil responses to light, measure the side vision, measure eye alignment and focusing ability when viewing a near target, and collect information about participants' symptoms. In a cross-over study design, the participants will then switch to sessions involving the other colored fixation light target for another 12 weeks, with data being again collected every 6 weeks. Potential differences in pupil responses to light between the treatment groups will be assessed as an objective outcome measure and compared to subjective symptom survey information. Thus, this work will test the hypothesis that daily fixation training using a blue light target can alleviate light intolerance in participants after head injury more than fixation training with a red light target, and this improvement is associated with altered pupil responses to light. As a significant minority of eye care clinicians currently utilize this approach in this population of patients, this study has the potential to influence clinical practice patterns whether the fixation training is shown to be effective or not.",[567],"Traumatic Brain Injury (TBI) Patients",[569,570,571],"traumatic brain injury","concussion","photophobia","2026-05-21",{"date":410,"type":36},{"date":575,"type":36},"2005-01",{"date":577,"type":23},"2026-12",{"name":42,"class":43},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":4,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":586,"enrollmentInfo":587,"targetDuration":4,"studyType":24,"phases":588,"briefSummary":589,"conditions":590,"keywords":593,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":595,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":68},"100525193","3d-printing-to-improve-nasal-irrigation-outcome-100525193","NCT06118554","3D Printing to Improve Nasal Irrigation Outcome","3D Printing for Topical Nasal Corticosteroid Irrigations: a Randomized Clinical Trial.","Inclusion Criteria:\n\n* Chronic rhinosinusitis without nasal polyps (CRSsNP) or Chronic rhinosinusitis with nasal polyps (CRSwNP).\n\nExclusion Criteria:\n\n* Patients with significant nasal polyps (as determined by a clinician) were excluded upfront due to the unlikeness of irrigation penetration regardless of the head position. Patients with significant atopy, cystic fibrosis, granulomatosis with polyangiitis or other connective tissue disorder, and current pregnancy were also excluded.","75 Years",{"count":119,"type":23},[91],"Three-dimensional (3D) printing has been an emerging technology with uses in a wide array of fields. This research aims to use 3D printing as a tool to provide personalized education to maximize treatment efficacy based on the patient's individual anatomy. With increased irrigation to the sinuses, we hypothesize there will be improved patient satisfaction and higher quality of life. The outcomes of this research could lead to a new option for patients who live with chronic rhinosinusitis are not candidates for surgery or are interested in less invasive options. The 3D printed nasal replica is not something that would be implanted, rather it is a hand-held device used specifically for participants to better understand their nasal anatomy.",[591,592],"Chronic Rhinosinusitis With Nasal Polyps","Chronic Rhinosinusitis Without Nasal Polyps",[594],"3D modeling",{"date":410,"type":36},{"date":597,"type":36},"2021-11-01",{"date":599,"type":23},"2027-12-30",{"name":42,"class":43},{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":17,"sex":18,"minAge":53,"maxAge":461,"enrollmentInfo":608,"targetDuration":4,"studyType":24,"phases":610,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":68},"100509968","nasal-obstruction-and-olfactory-losses-100509968","NCT05920330","Nasal Obstruction and Olfactory Losses","Novel Mechanisms and Therapeutic Approaches for Nasal Obstruction and Olfactory Losses","Inclusion Criteria:\n\n1. Smell Loss complaints\n2. Nasal Obstruction\n\nExclusion Criteria:\n\n1. Congenital olfactory losses\n2. Nasal polyps, blocking the olfactory cleft\n3. Significant atrophy\n4. Cystic fibrosis\n5. Wegeners or any other connective tissue disorder\n6. Head trauma",{"count":609,"type":23},330,[91],"About 13% of US adults, some 30 million people, suffer from nasal sinus disease. Although nasal obstruction and smell loss are two of the major symptoms of the disease that are crucial to disease management, currently there is a lack of clinical tools to effectively evaluate the mechanisms contributing to these symptoms. The proposed study aims to develop novel clinical tools to better evaluate and relieve patients' nasal obstructive symptoms and to enable patients and clinicians to make more informed, personalized decisions regarding treatment strategy.",[613],"Nasal Obstruction",{"date":410,"type":36},{"date":616,"type":36},"2023-01-25",{"date":618,"type":23},"2028-12-31",{"name":42,"class":43},""]